Fei Fei, Li Sanzhong, Fei Zhou, Chen Zhinan
a 1 Department of Ophthalmology, Xijing Hospital, Fourth Military Medical University, Xi'an 71032, P.R. China.
b 2 Department of Cell Biology, College of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, P.R. China.
Expert Rev Anticancer Ther. 2015;15(11):1351-9. doi: 10.1586/14737140.2015.1092874. Epub 2015 Sep 28.
Gliomas are characterized by their invasiveness, angiogenesis, glycolysis and poor prognosis. Determining how to inhibit angiogenesis and glycolysis and induce cell death in gliomas is essential to the development of an effective therapy. CD147, a highly glycosylated transmembrane glycoprotein with two Ig-like extracellular domains that belongs to the immunoglobulin superfamily, plays an important role in the regulation of tumor invasiveness, angiogenesis and glycolysis by inducing the secretion of matrix metalloproteinases and vascular endothelial growth factor and by interacting with monocarboxylate transporters. In this review, we first summarize the roles played by CD147 in gliomas and then propose that CD147 may be a complementary prognostic biomarker and a possible therapeutic target for glioma treatment.
胶质瘤的特点是具有侵袭性、血管生成、糖酵解以及预后不良。确定如何抑制胶质瘤中的血管生成和糖酵解并诱导细胞死亡对于有效治疗方法的开发至关重要。CD147是一种高度糖基化的跨膜糖蛋白，属于免疫球蛋白超家族，具有两个Ig样细胞外结构域，通过诱导基质金属蛋白酶和血管内皮生长因子的分泌以及与单羧酸转运体相互作用，在肿瘤侵袭、血管生成和糖酵解的调节中发挥重要作用。在本综述中，我们首先总结了CD147在胶质瘤中所起的作用，然后提出CD147可能是一种补充性的预后生物标志物以及胶质瘤治疗的一个潜在治疗靶点。
